• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗痉挛药物（钙拮抗剂和/或硝酸异山梨酯）对无血流动力学显著意义的冠状动脉疾病的冠状动脉痉挛性心绞痛患者高敏C反应蛋白的影响。

Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease.

作者信息

Hung Ming-Jui, Cherng Wen-Jin, Cheng Chi-Wen, Yang Ning-I

机构信息

Cardiology Section, Department of Medicine, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan.

出版信息

Am J Cardiol. 2005 Jan 1;95(1):84-7. doi: 10.1016/j.amjcard.2004.08.064.

DOI:10.1016/j.amjcard.2004.08.064
PMID:15619396
Abstract

Levels of high-sensitivity C-reactive protein were measured before and after 3 months of treatment with antispastic agents (calcium antagonists and/or isosorbide dinitrate) in 27 patients who had coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease. Levels of high-sensitivity C-reactive protein decreased after treatment with antispastic agents.

摘要

在27例患有冠状动脉痉挛性心绞痛且无血流动力学显著意义的冠状动脉疾病的患者中，测量了使用抗痉挛药物（钙拮抗剂和/或硝酸异山梨酯）治疗3个月前后的高敏C反应蛋白水平。使用抗痉挛药物治疗后，高敏C反应蛋白水平降低。

相似文献

1
Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease.抗痉挛药物（钙拮抗剂和/或硝酸异山梨酯）对无血流动力学显著意义的冠状动脉疾病的冠状动脉痉挛性心绞痛患者高敏C反应蛋白的影响。
Am J Cardiol. 2005 Jan 1;95(1):84-7. doi: 10.1016/j.amjcard.2004.08.064.
2
[Drug therapy in angina pectoris].[心绞痛的药物治疗]
Praxis (Bern 1994). 1995 Oct 17;84(42):1186-9.
3
[The clinical evaluation of the efficacy of Isoket in patients with vasospastic stenocardia].[异舒吉治疗血管痉挛性心绞痛患者疗效的临床评估]
Ter Arkh. 1992;64(9):39-42.
4
[Disease activities and serum C-reactive protein levels in patients with vasospastic angina pectoris].[变异性心绞痛患者的疾病活动度与血清C反应蛋白水平]
J Cardiol. 2005 Aug;46(2):63-70.
5
Clinical efficacy of benidipine for vasospastic angina pectoris.贝尼地平治疗血管痉挛性心绞痛的临床疗效。
Arzneimittelforschung. 2007;57(1):20-5. doi: 10.1055/s-0031-1296581.
6
Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease.无血流动力学显著意义的冠状动脉疾病患者中高敏C反应蛋白水平与冠状动脉痉挛性心绞痛的关系。
Am J Cardiol. 2005 Dec 1;96(11):1484-90. doi: 10.1016/j.amjcard.2005.07.055. Epub 2005 Oct 11.
7
[Transcutaneous application of nitroglycerin and isosorbide dinitrate versus placebo: effect in myocardial ischemia].
Schweiz Med Wochenschr. 1985 Mar 23;115(12):412-7.
8
[The role of calcium antagonists on coronary artery spasm and prevention of restenosis after angioplasty].
Przegl Lek. 1997;54(1):37-42.
9
What is optimal drug therapy in angina pectoris?
Cardiovasc Clin. 1983;13(1):209-20.
10
[Coronary spastic angina refractory to optimal medical therapy treated by angioplasty and stenting. A case report and review of literature].[经血管成形术和支架置入术治疗的对最佳药物治疗无效的冠状动脉痉挛性心绞痛。病例报告及文献复习]
Ann Cardiol Angeiol (Paris). 2010 Apr;59(2):103-6. doi: 10.1016/j.ancard.2008.07.004. Epub 2008 Aug 22.

引用本文的文献

1
Rare Clinical Manifestation of Vasculitis.血管炎的罕见临床表现
Diagnostics (Basel). 2024 Nov 22;14(23):2623. doi: 10.3390/diagnostics14232623.
2
Contemporary Diagnosis and Management of Patients with MINOCA.MINOCA 患者的当代诊断与管理。
Curr Cardiol Rep. 2023 Jun;25(6):561-570. doi: 10.1007/s11886-023-01874-x. Epub 2023 Apr 17.
3
Relationship between Inflammation and Vasospastic Angina.炎症与血管痉挛性心绞痛的关系。
Medicina (Kaunas). 2023 Feb 9;59(2):318. doi: 10.3390/medicina59020318.
4
MINOCA: One Size Fits All? Probably Not-A Review of Etiology, Investigation, and Treatment.心肌梗死伴非阻塞性冠状动脉病变：一种通用的治疗方法？可能并非如此——病因、检查及治疗综述
J Clin Med. 2022 Sep 20;11(19):5497. doi: 10.3390/jcm11195497.
5
Pathobiology and evolving therapies of coronary artery vasospasm.冠状动脉痉挛的病理生物学与不断发展的治疗方法
Proc (Bayl Univ Med Cent). 2021 Apr 21;34(3):352-360. doi: 10.1080/08998280.2021.1898907.
6
Coronary artery spasm: Current knowledge and residual uncertainties.冠状动脉痉挛：当前认知与遗留的不确定性
Int J Cardiol Heart Vasc. 2016 Jan 23;10:47-53. doi: 10.1016/j.ijcha.2016.01.003. eCollection 2016 Mar.
7
Impact of Asthma on the Development of Coronary Vasospastic Angina: A Population-Based Cohort Study.哮喘对冠状动脉痉挛性心绞痛发生发展的影响：一项基于人群的队列研究。
Medicine (Baltimore). 2015 Oct;94(42):e1880. doi: 10.1097/MD.0000000000001880.
8
Chronic kidney disease stage is a modulator on the association between high-sensitivity C-reactive protein and coronary vasospastic angina.慢性肾脏病分期是高敏C反应蛋白与冠状动脉痉挛性心绞痛之间关联的调节因素。
ScientificWorldJournal. 2014 Mar 5;2014:852507. doi: 10.1155/2014/852507. eCollection 2014.
9
Effect of erythropoietin-stimulating agent on uremic inflammation.促红细胞生成素刺激剂对尿毒症炎症的影响。
J Inflamm (Lond). 2012 May 14;9(1):17. doi: 10.1186/1476-9255-9-17.
10
Current advances in the understanding of coronary vasospasm.冠状动脉痉挛认识的当前进展
World J Cardiol. 2010 Feb 26;2(2):34-42. doi: 10.4330/wjc.v2.i2.34.